Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (NASDAQ: SNWV) is a medical technology company that focuses on patented, non-invasive directed energy systems used in advanced wound care and tissue regeneration. Its press releases emphasize research, development, and commercialization of medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, as well as applications in orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
The SNWV news feed highlights quarterly and annual financial results, including revenue trends, gross margin, operating income, and non-GAAP measures such as EBITDA and Adjusted EBITDA. Investors can follow updates on record quarterly revenues, changes in revenue mix driven by UltraMIST systems and consumables, and management commentary on market conditions in the wound care space.
News items also cover business updates and reimbursement developments. Sanuwave has issued releases discussing proposed and final rules from the Centers for Medicare & Medicaid Services (CMS) for the Physician Fee Schedule, particularly reimbursement for CPT code 97610 associated with UltraMIST procedures. These updates explain how reimbursement levels for physician offices, home visits, long-term care, and hospital settings relate to the company’s expectations.
Additional coverage includes strategic and corporate events, such as a secured credit facility with JPMorgan Chase Bank, N.A. used to refinance a prior debt facility, a license and option agreement related to intravascular shockwave patents, and participation in healthcare industry conferences. The news stream also reports on governance and executive changes disclosed in Form 8-K filings, as well as announcements of conference calls to discuss financial results.
By reviewing the SNWV news page, readers can see how Sanuwave communicates its financial performance, reimbursement environment, capital structure decisions, and ongoing activities in advanced wound care and regenerative medicine.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.